Maiwei Biotech (688062.SH) disclosed its 2023 annual report. During the reporting period, the company achieved revenue of 128 million yuan, an increase of 361.03%; net profit loss to mother of 1,053 million yuan, a year-on-year increase; loss of 1.06 billion yuan after deducting non-net profit, a large year-on-year loss; and basic earnings per share of -2.64 yuan.
迈威生物(688062.SH)发布2023年度业绩，净亏损10.53亿元，亏损同比扩大
Maiwei Biotech (688062.SH) announced its 2023 annual results, with a net loss of 1,053 billion yuan, an increase in losses over the same period last year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.